Condition: Oropharynx Squamous Cell Carcinoma · Sponsor: UNICANCER
SURVEILLE-HPV - A new post therapeutic surveillance strategy for HPV-driven oropharyngeal cancer based on HPV Circulating DNA measures. HPV-positive oropharyngeal cancer patients have a much better prognosis that their HPV-negative counterparts. Despite this, Post Treatment Surveillance (PTS) strategy does not take into account HPV status. HPV Circulating DNA (HPV Ct DNA) has emerged as a promising tool to assess the risk of cancer recurrence following treatment. We assume that this biomarker could be helpful to guide PTS. The number of systematic PTS visits could be significantly reduced in patients with undetectable HPV Ct DNA whereas a closer clinical and radiological follow up could be performed in case of detectable HPV Ct DNA. If confirmed, this new strategy could have several benefits including: * reduction of PTS visits for most HPV-positive patients which implies a potential cost decrease and * Identification of relapse at early stages (before the occurrence of symptoms)
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Clinique St Vincent- Réunion | Saint-Denis, La Réunion, France | Active Not Recruiting |
| ISC Avignon | Avignon, France | Recruiting |
| Georges-François Leclerc | Dijon, France | Recruiting |
| Oscar Lambret- Lille | Lille, France | Not Yet Recruiting |
| La Timone-AP-HM Marseille | Marseille, France | Recruiting |
| Antoine Lacassagne - NICE | Nice, France | Active Not Recruiting |
| CHU De Nîmes ICG | Nîmes, France | Active Not Recruiting |
| Hôpital Européen Georges Pompidou | Paris, France | Recruiting |
| Institut Curie - Paris | Paris, France | Not Yet Recruiting |
| TENON - APHP Paris | Paris, France | Recruiting |
| Eugène Marquis-Rennes | Rennes, France | Recruiting |
| ICO - Site St Herblain | Saint-Herblain, France | Not Yet Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05582122